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Background: Patients with malignant disease frequently present with activated coagulation pathways, which are
potentially associated with tumor progression and prognosis. The aims of the study were to investigate the clinical
significance of preoperative plasma fibrinogen level and platelet count in esophageal squamous cell carcinoma
(ESCC) treated by curative surgery.
Methods: A total of 119 patients with ESCC treated by curative surgery in Qilu Hospital of Shandong University
were included in the study.
Results: The preoperative plasma fibrinogen levels in the patients with ESCC ranged from 2.2 to 6.91 g/L (mean ± SD,
3.85 ± 0.95 g/L). The incidence of hyperfibrinogenemia was 43.7% (52/119, cut-off value 4.0 g/L). Hyperfibrinogenemia
was found to be positively correlated with increased tumor length (P = 0.027), increased depth of invasion (P = 0.013),
advanced pathological stages (P = 0.011), and disease recurrence (P = 0.026). The platelet counts ranged from 78 × 109/L
to 936 × 109/L (mean ± SD, 254.51 ± 89.26 × 109/L). The incidence of thrombocytosis was 20.2% (24/119, cut-off value
300 × 109/L). Thrombocytosis was more frequently seen in male gender (P = 0.029) and non-smokers (P = 0.008). Plasma
fibrinogen levels were significantly correlated with platelet counts (r = 0.018, P = 0.048). Hyperfibrinogenemia was
significantly associated with poor disease-free (P = 0.009, hazard ratio (HR) = 1.784, 95% confidence interval (CI) = 1.153
to 2.761) and overall (P = 0.003, HR = 1.992, 95% CI = 1.259 to 3.152) survivals in univariate analysis, but not an independent
prognostic indicator in multivariate analysis. Thrombocytosis was not significantly associated with disease-free (P = 0.765,
HR = 0.918, 95% CI = 0.524 to 1.608) or overall (P = 0.809, HR = 1.072, 95% CI = 0.618 to 1.891) survivals in univariate analysis.
Conclusions: The study suggested that hyperfibrinogenemia is a valuable predictor for disease progression in ESCC.
Anticoagulation therapy might be considered to control cancer progression in future studies.
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Esophageal cancer is the eighth most common cancer
type and sixth leading cause of cancer death worldwide,
which was responsible for 482,300 new cases and
406,800 deaths in 2008 [1]. In some high-risk regions
such as North of China, esophageal cancer represents a
major health problem, which is the fourth leading cause
of cancer death. Squamous cell carcinoma is the major
pathological type and accounts for more than 90% of* Correspondence: qlcyf1965@163.com
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unless otherwise stated.esophageal cancer cases in Chinese patients [2]. Despite
the advancement in diagnosis and treatment modalities,
esophageal squamous cell carcinoma (ESCC) still shows
a dismal prognosis with a 5-year survival rate less than
15% [3,4]. It is important to identify effective biomarkers
to recognize unique biological characteristics of ESCC
patients, in order to guide more individualized treatment.
It has been demonstrated that the alteration of coagula-
tion pathways was associated with tumor progression and
poor prognosis in various malignancies [5,6]. More than
half of patients with metastatic disease have some abnor-
malities in hemostatic parameters [7]. Fibrinogen is a
dimeric glycoprotein synthesized by hepatocytes, whichThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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binds to platelets to support platelet aggregation after
being converted to fibrin. Elevated plasma fibrinogen
levels reflect a thrombophilic state that arises from the
capacity of tumor cells to release coagulant molecules [8].
Fibrinogen is also a pro-inflammatory protein, which usu-
ally acts as an acute-phase protein in response to wound
healing, infection, and inflammation [9]. Recently, the
plasma fibrinogen level was found to correlate with clini-
copathological factors and prognosis in gastric cancer,
colon cancer, endometrial cancer, and so on [5,10,11].
Platelet is another crucial player of the coagulation system.
Platelet could facilitate metastasis through promoting dis-
seminated tumor cell survival in the circulation system,
and extravasation and angiogenesis in the microenviron-
ment of target sites [12]. Several studies have demon-
strated that an elevated platelet count correlate with poor
prognosis in several types of solid cancer, including lung
cancer, colorectal cancer, gastric cancer, and so on [13-15].
However, the exact role of plasma fibrinogen level and
platelet count in ESCC remains inconclusive.
In the present study, we examined the clinical signifi-
cance of preoperative plasma fibrinogen level and platelet
count in ESCC treated by curative surgery.
Methods
Patients
A total of 119 patients who underwent potential radical
surgery for ESCC in Qilu Hospital of Shandong University
between 1 January and 30 September 2008 were included
in the study. Patients were already excluded because of
palliative surgery, neoadjuvant treatment, perioperative
mortality, distant metastasis, stage 0 disease, and lost to
follow-up. The protocol of the study was approved by the
Institutional Ethics Committee of the Qilu Hospital of
Shandong University. All the patient demographic and
clinical data including age, gender, histological grade, lymph
node status, pTNM stage, and adjuvant treatment were
abstracted from the clinical records. The stage of disease
was determined according to the TNM system of the Inter-
national Union Against Cancer (6th edition). A thorough
histological examination was made using H&E-stained tis-
sue preparations and the histological grade was determined
according to the degree of differentiation of the tumor.
Fibrinogen and platelet measurement
As a part of clinical routine, the pretreatment plasma fi-
brinogen levels and platelet counts were measured from
early morning samples and were collected 24 h to 1 week
before surgery after overnight fasting. Plasma fibrinogen
levels and platelet counts greater than 4.0 g/L and 300 ×
109/L were defined as hyperfibrinogenemia and thrombo-
cytosis, respectively, according to the normal reference
range in our hospital.Follow up
Follow-up visit was performed every 3 months for the
first 2 years and every 6 months for the next up to death
or the end of the study. Data was censored at the last
follow-up for patients without recurrence or death. At
each visit, a clinical history was taken and a physical
examination was performed. Routing diagnostic imaging
methods included barium meal fluoroscopy and computer
tomography. Disease-free survival (DFS) was defined from
the date of the definitive surgery to the date of local or
distant recurrence, mortality by any cause, or the last
follow-up. Overall survival (OS) was calculated as the time
from the date of surgery to that of mortality or censoring.Statistical analysis
Pretreatment plasma fibrinogen levels and platelet counts
were reported as the mean ± SD. Continuous variables in
different subgroups were compared using an unpaired t-test
and one-way analysis of variance. Categorical variables were
compared using chi-square test. Bivariate correlation ana-
lysis was performed using Pearson’s correlation coefficient
analysis. Kaplan-Meier curves were used to estimate the
distribution of DFS and OS, and log-rank test was per-
formed to compare the difference between the survival
curves. Variables, which were identified as statistically
significant in univariate analysis, were included in the
multivariate survival analysis using the Cox proportional
hazard model. All statistical analyses were performed using
SPSS 13.0 statistical software (SPSS Inc, Chicago, IL, USA).
P values <0.05 were considered of statistical significance.Results
Patient characteristics
Median age was 60 years (range, 42 to 78 years), and
80% of patients were male. Tumor locations were upper
thoracic in 15 patients, mid-thoracic in 67 patients, and
lower thoracic in 37 patients. The mean length of the
tumor was 3.85 cm (range, 0.5 to 8.5). The histopatho-
logical differentiations were poor in 35 cases, moderate
in 51 cases, and well in 33 cases. 75 patients (63%) had
T3/T4 tumors. Forty-four patients (27%) have positive
lymph nodes. The pathological stages were stage I in 21
patients, stage II in 58 patients and stage III in 40
patients. 71 patients (59.7%) received surgery alone, 11
(9.2%) received postoperative chemotherapy, 25 (21%)
received postoperative radiotherapy, and 12 (10.1%)
received postoperative chemoradiation. Eighty-one
patients (68.1%) had recurrence, and 74 (62.2%) died
during the follow-up. The estimated 1-, 3-, and 5-year
DFS and OS rates were 75%, 49%, and 37% and 87%,
55%, and 41%, respectively. Median DFS was 33.8 months
(range, 1.5 to 71.5 months). Median OS was 45.8 months
(range, 2.6 to 71.5 months).
Table 1 Relationship of preoperative plasma fibrinogen level with clinicopathological parameter
Variable N Fibrinogen level P value Fibrinogen level P value
Mean ± SD Normal Hyperfibrinogenemia
(g/L) (1.5 to 4 g/L) (≥4 g/L)
Gender
Male 95 3.94 ± 0.98 0.034 51 44 0.252
Female 24 3.48 ± 0.73 16 8
Age
<60 59 3.7 ± 0.94 0.101 38 21 0.077
≥60 60 3.99 ± 0.95 29 31
Smoking history
Yes 71 3.91 ± 0.95 0.371 29 19 0.457
No 48 3.75 ± 0.96 38 33
Location
Upper 15 3.56 ± 0.74 0.144 9 6 0.528
Middle 67 3.78 ± 0.99 40 27
Lower 37 4.08 ± 0.93 18 19
Tumor length
<3.85 cm 64 3.56 ± 0.88 <0.001 42 22 0.027
≥3.85 cm 55 4.18 ± 0.93 25 30
Differentiation
Well 33 3.94 ± 0.81 0.782 17 16 0.676
Moderate 51 3.81 ± 1.09 31 20
Poor 35 3.8 ± 0.87 19 16
Tumor stage
T1 18 3.25 ± 0.68 0.001 15 3 0.013
T2 26 3.67 ± 0.91 17 9
T3 67 3.97 ± 0.92 33 34
T4 8 4.69 ± 1.11 2 6
Lymph node status
Negative 75 3.77 ± 0.94 0.267 46 29 0.149
Positive 44 3.97 ± 0.97 21 23
Pathological stages
I 21 3.48 ± 0.81 0.034 15 6 0.011
II 58 3.79 ± 0.98 37 21
III 40 4.12 ± 0.91 15 25
Adjuvant treatment
None 71 3.87 ± 0.95 0.962 37 34 0.307
Radiotherapy 25 3.83 ± 0.97 13 12
Chemotherapy 11 3.9 ± 0.82 8 3
CRT 12 3.72 ± 1.11 9 3
Recurrence
Yes 81 3.94 ± 0.97 0.116 40 41 0.026
No 38 3.65 ± 0.89 27 11
SD, standard deviation; CRT, chemoradiotherapy. P < 0.05 is of significance.
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Table 2 Relationship of preoperative platelet count with clinicopathological parameters
Variable N Platelet count P value Platelet count P value
Mean ± SD Normal Thrombocytosis
(×109/L) <300 × 109/L ≥300 × 109/L
Gender
Male 95 260.79 ± 96.13 0.127 72 23 0.029
Female 24 229.67 ± 47.93 23 1
Age
<60 59 254.86 ± 68.78 0.966 46 13 0.615
≥60 60 254.17 ± 106.22 49 11
Smoking history
Yes 71 267.39 ± 105.4 0.055 44 4 0.008
No 48 235.46 ± 53.23 51 20
Location
Upper 15 260.93 ± 82.51 0.696 12 3 0.964
Middle 67 248.36 ± 59.93 54 13
Lower 37 263.05 ± 129.3 29 8
Tumor length
<3.85 cm 64 250.18 ± 103.94 0.571 54 10 0.183
≥3.85 cm 55 259.54 ± 68.96 41 14
Differentiation
Well 33 263.39 ± 136.03 0.793 26 7 0.568
Moderate 51 250.04 ± 69.68 39 12
Poor 35 252.66 ± 54.62 30 5
Tumor stage
T1 18 207.56 ± 51.84 0.034 17 1 0.251
T2 26 247.58 ± 53.27 21 5
T3 67 263.66 ± 105.27 52 15
T4 8 306.13 ± 58.73 5 3
Lymph node status
Negative 75 250.89 ± 99.45 0.566 62 13 0.314
Positive 44 260.68 ± 69.14 33 11
Pathological stages
I 21 258.19 ± 168.65 0.233 17 4 0.636
II 58 246.48 ± 54.6 48 10
III 40 264.23 ± 70.43 30 10
Adjuvant treatment
None 71 259.69 ± 105.06 0.823 56 15 0.788
Radiotherapy 25 253.48 ± 65.68 20 5
Chemotherapy 11 235.55 ± 43.03 10 1
CRT 12 243.42 ± 58.82 9 3
Recurrence
Yes 251.44 ± 58.06 0.675 66 15 0.513
No 261.05 ± 134.37 29 9
SD, standard deviation; CRT, chemoradiotherapy. P < 0.05 is of significance.
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and clinicopathological parameters
The plasma fibrinogen levels in preoperative esophageal
cancer patients ranged from 2.2 to 6.91 g/L (mean ± SD
3.85 ± 0.95 g/L). The incidence of hyperfibrinogenemia
was 43.7% (52/119, cut-off value 4.0 g/L). Hyperfibrino-
genemia was found to be positively correlated with a
larger tumor size (P = 0.027), increased depth of invasion
(P = 0.013), advanced pathological stages (P = 0.011), and
disease recurrence (P = 0.026). No significant correlation
was identified between fibrinogen levels and tumor loca-
tion or lymph node metastasis (Table 1).
The platelet counts ranged from 78 × 109/L to 936 ×
109/L (mean ± SD 254.51 ± 89.26 × 109/L). The incidence
of thrombocytosis was 20.2% (24/119, cut-off valueTable 3 Univariate analysis of survival of esophageal squamo
Variable Disease-free survival
HR (95% CI)
Gender (Female) 0.939(0.535 to 1.647)
Age (≥60) 0.982(0.634 to 1.519)
Smoking history 1.093(0.697 to 1.717)
Location
Upper Ref.
Middle 0.656(0.346 to 1.246)
Lower 0.694(0.349 to 1.378)
Tumor length (≥3.85 cm) 1.178(0.761 to 1.824)
Differentiation
Well Ref.
Moderate 1.595(0.915 to 2.781)
Poor 1.616(0.889 to 2.939)
Tumor stage
T1 Ref.
T2 1.388(0.612 to 3.149)
T3 2.295(1.117 to 4.713)
T4 4.112(1.568 to 10.786)
Lymph node metastasis 2.406(1.544 to 3.749)
Pathological stages
I Ref.
II 1.97(0.944 to 4.113)
III 4.96(2.35 to 10.471)
Adjuvant treatment
None Ref.
Radiotherapy 1.672(0.984 to 2.839)
Chemotherapy 0.732(0.312 to 1.714)
CRT 1.549(0.756 to 3.174)
Fibrinogen level (≥4 g/L) 1.784(1.153 to 2.761)
Platelet count (≥300 × 109 /L) 0.918(0.524 to 1.608)
HR, hazard ratio; CI, confidence interval; CRT, chemoradiotherapy. P < 0.05 is of sign300 × 109/L). Thrombocytosis was more frequently seen
in male gender (P = 0.029) and non-smokers (P = 0.008).
There was no significant correlation between the platelet
count and the larger tumor size, increased depth of inva-
sion, advanced pathological stages, or disease recurrence
(Table 2). A significant correlation between plasma
fibrinogen levels and platelet counts was observed (r =
0.018, P = 0.048).
Survival analysis
We assessed the prognostic values of the preoperative
plasma fibrinogen level and platelet count in the ESCC pa-
tients included in our study, as shown in Table 3. Patients
with hyperfibrinogenemia had lower 5-year disease-free
survival (27% vs. 45%) and overall survival rates (29% vs.us cell carcinoma treated by curative surgery
P value Overall survival P value
HR (95% CI)
0.826 0.937(0.523 to 1.677) 0.826
0.933 1.09(0.69 to 1.721) 0.712
0.698 1.139(0.712 to 1.825) 0.587
0.432 Ref. 0.652
0198 0.721(0.36 to 1.442) 0.355
0.296 0.771(0.368 to 1.614) 0.49
0.462 1.335(0.846 to 2.106) 0.215
0.2 Ref. 0.141
0.1 1.69(0.931 to 3.067) 0.084
0.116 1.819(0.965 to 3.427) 0.064
0.011 Ref. 0.001
0.432 1.591(0.605 to 4.188) 0.347
0.024 3.19(1.36 to 7.481) 0.008
0.004 5.968(2.058 to 17.301) 0.001
<0.001 2.414(1.522 to 3.829) <0.001
<0.001 Ref. <0.001
0.071 2.561(1.069 to 6.133) 0.035
<0.001 6.412(2.669 to 15.404) <0.001
0.133 Ref. 0.073
0.057 1.814(1.058 to 3.111) 0.03
0.472 0.652(0.258 to 1.65) 0.367
0.232 1.521(0.712 to 3.249) 0.279
0.009 1.992(1.259 to 3.152) 0.003
0.765 1.072(0.618 to 1.891) 0.809
ificance.
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tration. In univariate analysis, hyperfibrinogenemia was
associated with poor disease-free (P = 0.009, hazard ratio
(HR) = 1.784, 95% confidence interval (CI) = 1.153 to
2.761) and overall (P = 0.003, HR = 1.992, 95% CI = 1.259
to 3.152) survivals (Figure 1). Thrombocytosis was notFigure 1 Kaplan-Meier analysis of preoperative plasma fibrinogen level in 1
Hyperfibrinogenemia were significantly associated with decreased disease-correlated with disease survivals. Clinicopathological fac-
tors, which significantly associated with poor disease-free
and overall survivals, were advanced T stages, lymph node
metastasis, and advanced pTNM stages. In multivariate
analysis, only pTNM stages were an independent
predictor for disease-free survival (P < 0.001, HR = 2.985,19 patients with esophageal squamous cell carcinoma.
free survival (A) and overall survival (B).
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(P = 0.025, HR = 1.895, 95% CI = 1.084 to 3.313) and pTNM
stages (P < 0.001, HR = 2.501, 95% CI = 1.52 to 4.114) were
independent prognostic factors for overall survival.
Discussion
Recently, much attention has been paid to the relationship
between hyperfibrinogenemia/thrombocytosis and malig-
nant diseases. Elevated plasma fibrinogen levels and plate-
let counts have been found in some malignancies, such as
gastric cancer, colorectal cancer, lung cancer, and so on
[11,16-18]. In the present study, we analyzed the clinical
significance of preoperative plasma fibrinogen level and
platelet count in 119 patients with ESCC received curative
surgery. We found that the incidence of hyperfibrinogen-
emia and thrombocytosis were 43.7% (52/119, cut-off value
4.0 g/L) and 20.2% (24/119, cut-off value 300 × 109/L), re-
spectively, in the resectable ESCC patients. Hyperfibrino-
genemia was found to be positively correlated with the
increased tumor length, increased depth of invasion, and
advanced pathological stages. Hyperfibrinogenemia was
associated with poor disease-free and overall survivals in
univariate analysis, but not an independent predictor for
prognosis in multivariate analysis. Thrombocytosis was not
associated with clinical outcome and clinicopathological
parameters such as depth of invasion, lymph node metasta-
sis, or pathological stages. We also observe a significant
correlation plasma fibrinogen levels and platelet counts
(r = 0.018, P = 0.048).
To our best knowledge, only two studies analyzed the
clinical significance of plasma fibrinogen in ESCC. Takeuchi
et al. [19] showed that pretreatment plasma fibrinogen cor-
relates with tumor progression and metastasis in patients
with ESCC. However, they did not show any association of
pretreatment plasma fibrinogen with survivals in patients
treated by surgery. Matsuda and colleagues [20] found that
plasma fibrinogen level as a predictive marker for postoper-
ative recurrence of ESCC in patients receiving neoadjuvant
treatment. In the study, we firstly analyzed the clinical sig-
nificance of pretreatment plasma fibrinogen in 119 ESCC
treated by curative surgery without neoadjuvant treatment.
Our study showed that hyperfibrinogenemia was signifi-
cantly associated with advanced disease.
For thrombocytosis, the role of its prognostic signifi-
cance is also inconclusive. Feng et al. [21] analyzed the
clinical significance of preoperative thrombocytosis in a
group of patients with ESCC and found that preoperative
platelet count is a predictive factor for long-term survival
in ESCC, especially in node-positive patients. Shimada
et al. [22] found that a high platelet count is associated
with tumor progression and poor survival in patients with
esophageal cancer. However, the present study did not
show that thrombocytosis was associated with clinical out-
come and any pathological parameters in ESCC treat bycurative surgery. The reason for the inconsistent results
may be that our study included patients with relative early
stage compared with previous studies.
The exact mechanism linking coagulation pathways and
cancer progression remains unclear. Fibrinogen is a di-
meric molecule with multiple integrin and non-integrin
binding motifs, and cancer cells often express high levels
of integrins or intercellular adhesion molecule 1. Fibrino-
gen deposition around tumor cells enhances the inter-
action between these cells and platelets, which effectively
form microemboli in target organs [23]. Fibrinogen may
also bind to growth factors, such as fibroblast growth fac-
tors and vascular endothelial cell growth factors, and
thereby regulate endothelial cell proliferation and angio-
genesis [24]. Fibrinogen layers help tumor cells block nat-
ural killer cytotoxicity with thrombin, which can protect
tumor cells from the innate immune system [25].
Platelets, which were produced by mature bone marrow
megakaryocytes, play an important role in arresting
hemorrhage after tissue trauma or vascular injury. Plate-
lets take an active part in the initiation and development
of the inflammatory process by adhering to the cells of the
vascular walls and by releasing of chemokines, cytokines,
proteases, and procoagulants [26]. Platelets release various
cytokines, including vascular endothelial growth factor
(VEGF) and platelet-derived growth factor (PDGF), during
blood clotting. The VEGF and PDGF family of proteins
have a significant role in regulating tumor cell growth and
angiogenesis [27]. Moreover, platelets expressing immuno-
regulatory protein such as glucocorticoid-induced TNF-
related protein may protect the cancer cells from the
host’s immune system [28].
The potential limitations of the present study include
the use of a retrospective design. In order to select
patients with a more uniform background, we only
included esophageal cancer patients treated by potential
curative surgery and excluded those received neoadjuvant
treatment, which may also limit the general application of
the results. Furthermore, larger prospective studies will be
needed to confirm these preliminary results.
Conclusions
Our study demonstrated that hyperfibrinogenemia is a
valuable predictor for disease progression in ESCC. Antic-
oagulation therapy might be considered to control cancer
progression in future studies. Additionally, the introduction
of the convenient prognostic factors such as plasma fibrino-
gen can assist clinicians with better individualization of
their therapeutic approach based on the risk stratification.
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